| abstract |
The present invention is for use in the prevention or treatment of pulmonary inflammation by neutrophil infiltration, for example in the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, bronchiolitis, acute lung injury and acute respiratory distress syndrome To provide a composition comprising a modified interleukin-8 (IL-8) having increased GAG binding affinity and more suppressed or down-regulated GPCR activity as compared to each wild type IL-8. |